Prelude Therapeutics Inc (PRLD) shareholders
Close on Nov 17, 2026Market cap $264.95MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp Vi LLC (14.60%) | 12,935,071 | 16.00% | 13D (active) amendment | Apr 21, 2026 |
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (15.50%), Baker Bros. Advisors (GP) LLC (15.50%) and 1 more | 10,295,301 | 15.50% | 13D (active) amendment | Apr 20, 2026 |
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (23.50%), Julian C. Baker (23.50%) and 1 more | 10,269,968 | 23.50% | 13D (active) amendment | Jun 12, 2025 |
| Vaddi Krishna | 6,745,647 | 13.15% | 13G (passive) amendment | Dec 31, 2025 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 6,477,309 | 9.90% | 13G (passive) | Apr 21, 2026 |
| Incyte Corp | 4,372,124 | 9.90% | 13G (passive) | Nov 3, 2025 |
| Levy Guy Joint filing with Soleus Capital Management, L.P. (5.20%), Soleus GP, LLC (5.20%) | 3,378,378 | 5.20% | 13G (passive) | Apr 21, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PRLD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 13,724,571 | 17.20% | $73.15M | +2,815,315 | 1.36% |
| Baker Bros. Advisors LP | 10,123,824 | 12.69% | $53.96M | – | 0.27% |
| Ra Capital Management, L.P. | 6,475,882 | 8.11% | $34.52M | New | 0.30% |
| Soleus Capital Management, L.P. | 3,378,378 | 4.23% | $18.01M | New | 0.62% |
| Kynam Capital Management, LP | 2,415,087 | 3.03% | $12.87M | +822,536 | 0.71% |
| Vanguard Capital Management LLC | 2,009,445 | 2.52% | $10.71M | +779,039 | 0.00% |
| BlackRock, Inc. | 1,797,501 | 2.25% | $9.58M | +1,475,615 | 0.00% |
| Sphera Funds Management Ltd. | 1,019,832 | 1.28% | $5.44M | +461,493 | 0.71% |
| Two Sigma Investments, LP | 993,369 | 1.24% | $5.29M | +69,743 | 0.00% |
| ADAR1 Capital Management, LLC | 900,900 | 1.13% | $4.80M | +748,075 | 0.22% |
| Millennium Management LLC | 844,993 | 1.06% | $4.50M | +462,256 | 0.00% |
| Geode Capital Management, LLC | 841,862 | 1.05% | $4.49M | +539,404 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 766,095 | 0.96% | $4.08M | New | 0.01% |
| Acadian Asset Management LLC | 611,359 | 0.77% | $3.25M | +99,840 | 0.00% |
| Morgan Stanley | 503,860 | 0.63% | $2.69M | +181,699 | 0.00% |
| State Street Corp | 428,787 | 0.54% | $2.29M | +290,556 | 0.00% |
| UBS Group AG | 318,797 | 0.40% | $1.70M | +254,292 | 0.00% |
| Vanguard Fiduciary Trust Co | 284,886 | 0.36% | $1.52M | +127,506 | 0.00% |
| Renaissance Technologies LLC | 281,200 | 0.35% | $1.50M | +6,000 | 0.00% |
| Northern Trust Corp | 240,599 | 0.30% | $1.28M | +190,479 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 75 | 50M | 62.2% | 34 / 25 | 8 / 13 | 21M | 2M |
| Q1 2026 | 55 | 31M | 38.6% | 13 / 20 | 12 / 5 | 5M | 1M |
| Q4 2025 | 48 | 28M | 35.7% | 10 / 15 | 14 / 9 | 3M | 2M |
| Q3 2025 | 47 | 27M | 34.0% | 5 / 8 | 23 / 8 | 1M | 1M |
| Q2 2025 | 50 | 27M | 34.1% | 8 / 13 | 22 / 17 | 1M | 4M |
| Q1 2025 | 59 | 31M | 38.3% | 5 / 18 | 24 / 7 | 1M | 2M |
| Q4 2024 | 62 | 32M | 40.3% | 8 / 26 | 12 / 16 | 4M | 8M |
| Q3 2024 | 70 | 36M | 44.8% | 17 / 20 | 20 / 7 | 5M | 2M |
| Q2 2024 | 61 | 34M | 42.5% | 10 / 16 | 21 / 7 | 0M | 1M |
| Q1 2024 | 58 | 35M | 43.6% | 7 / 17 | 21 / 5 | 1M | 1M |
| Q4 2023 | 56 | 35M | 43.9% | 6 / 30 | 13 / 10 | 5M | 7M |
| Q3 2023 | 60 | 37M | 45.9% | 7 / 24 | 16 / 2 | 1M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
55 funds held PRLD in Q2 2026, 77% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PRLD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,513,825 | 1.90% | $8.07M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 657,987 | 0.82% | $3.51M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 458,355 | 0.57% | $2.44M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 303,517 | 0.38% | $1.40M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 260,735 | 0.33% | $1.39M | 0.01% | Jun 30, 2026 |
| SIMT Tax-Managed Small/Mid Cap Fund | 182,119 | 0.23% | $970.69K | 0.13% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 127,839 | 0.16% | $501.13K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 93,079 | 0.12% | $496.11K | 0.03% | Jun 30, 2026 |
| Siit Small Cap Ii Fund | 82,100 | 0.10% | $321.83K | 0.13% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 67,622 | 0.08% | $311.06K | 0.00% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 61,000 | 0.08% | $325.13K | 0.22% | Jun 30, 2026 |
| Master Small Cap Index Series | 51,899 | 0.07% | $276.62K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 43,616 | 0.05% | $170.97K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 37,023 | 0.05% | $170.31K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 36,601 | 0.05% | $143.48K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Krishna Vaddi | CEO, Director | 2,693,623 | 3.38% | Feb 5, 2026 |
| Charles Q. Morris | Chief Medical Officer | – | – | May 4, 2026 |
| Sean P. Brusky | Chief Business Officer | 100,000 | 0.13% | Mar 19, 2026 |
| Peggy Scherle | Chief Scientific Officer | 173,527 | 0.22% | Feb 5, 2026 |
| Bryant David Lim | CLO, CFO, Corp Sec. | 27,400 | 0.03% | Feb 5, 2026 |
| Andrew Combs | Chief Chemistry Officer | 480,123 | 0.60% | Feb 5, 2026 |
| Jane Huang | President, CMO | 86,917 | 0.11% | Oct 7, 2025 |
| Victor Sandor | Director | – | – | Jun 10, 2026 |
| Katina Dorton | Director | – | – | Jun 10, 2026 |
| Paul A. Friedman | Director | 347,522 | 0.44% | Jun 10, 2026 |
| 667, L.P. | Director, 10% owner | – | – | Jun 10, 2026 |
| Bros. Advisors Lp Baker | Director, 10% owner | 876,061 | 1.10% | Jun 10, 2026 |
| Julian Baker | Director, 10% owner | – | – | Jun 10, 2026 |
| Felix Baker | Director, 10% owner | – | – | Jun 10, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | – | – | Jun 10, 2026 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 870,873 | 1.09% | Jun 10, 2026 |
| David P. Bonita | Director, 10% owner | 1,126,126 | 1.41% | Jun 10, 2026 |
| Martin Babler | Director | – | – | Jun 10, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 9,250,191 | 11.59% | Apr 23, 2026 |
| Capital GP VI LLC OrbiMed | Director, 10% owner | – | – | Apr 23, 2026 |
| Capital Llc Orbimed | Director, 10% owner | 10,119,756 | 12.68% | Apr 23, 2026 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 1,126,126 | 1.41% | Apr 23, 2026 |
| Paul C. Scherer | Director | – | – | Jun 13, 2025 |
| Mardi Dier | Director | 10,000 | 0.01% | Jun 13, 2025 |
| Peter Kolchinsky | 10% owner | – | – | Apr 28, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | – | – | Apr 28, 2026 |
| Rajeev M. Shah | 10% owner | 6,475,882 | 8.11% | Apr 28, 2026 |
| Ra Capital Management, L.P. | 10% owner | 7,882,882 | 9.88% | Apr 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rajeev M. Shah 10% owner | Apr 27, 2026 | Other | −1,407,000 | – | – | 6,475,882 |
| David P. Bonita Director, 10% owner | Apr 21, 2026 | Buy | +1,126,126 | $4.44 | $5.00M | 1,126,126 |
| David P. Bonita Director, 10% owner | Apr 21, 2026 | Buy | +1,689,189 | $4.44 | $7.50M | 11,808,945 |
| Genesis GP LLC OrbiMed Director, 10% owner | Apr 21, 2026 | Buy | +1,126,126 | $4.44 | $5.00M | 1,126,126 |
| Genesis GP LLC OrbiMed Director, 10% owner | Apr 21, 2026 | Buy | +1,689,189 | $4.44 | $7.50M | 11,808,945 |
| Jane Huang President, CMO | Oct 4, 2025 | Tax withholding | −3,355 | $1.47 | $4.93K | 86,917 |
| Jane Huang President, CMO | Oct 4, 2025 | Option exercise | +9,375 | – | – | 90,272 |
| Jane Huang President, CMO | Jul 4, 2025 | Tax withholding | −3,355 | $0.79 | $2.65K | 80,897 |
| Jane Huang President, CMO | Jul 4, 2025 | Option exercise | +9,375 | – | – | 84,252 |
| Jane Huang President, CMO | Apr 4, 2025 | Option exercise | +9,375 | – | – | 78,232 |
| Jane Huang President, CMO | Apr 4, 2025 | Tax withholding | −3,355 | $0.68 | $2.28K | 74,877 |
| Andrew Combs Chief Chemistry Officer | Mar 25, 2025 | Buy | +100,000 | $0.69 | $69.00K | 480,123 |
| Krishna Vaddi CEO, Director | Mar 25, 2025 | Buy | +675,000 | $0.69 | $465.75K | 1,999,296 |
| Krishna Vaddi CEO, Director | Mar 21, 2025 | Buy | +15,000 | $0.73 | $10.95K | 1,324,296 |
| Krishna Vaddi CEO, Director | Mar 20, 2025 | Buy | +5,416 | $0.73 | $3.95K | 1,309,296 |
| Krishna Vaddi CEO, Director | Mar 17, 2025 | Buy | +9,106 | $0.75 | $6.83K | 1,303,880 |
| Krishna Vaddi CEO, Director | Mar 14, 2025 | Buy | +29,999 | $0.75 | $22.50K | 1,294,774 |
| Krishna Vaddi CEO, Director | Mar 13, 2025 | Buy | +50,000 | $0.72 | $36.00K | 1,264,775 |
| Krishna Vaddi CEO, Director | Mar 12, 2025 | Buy | +47,500 | $0.71 | $33.73K | 1,214,775 |
| Jane Huang President, CMO | Jan 4, 2025 | Tax withholding | −3,859 | $1.39 | $5.36K | 68,857 |
| Jane Huang President, CMO | Jan 4, 2025 | Option exercise | +9,375 | – | – | 72,716 |
| Krishna Vaddi CEO, Director | Dec 31, 2024 | Buy | +5,000 | $1.21 | $6.05K | 142,553 |
| Krishna Vaddi CEO, Director | Dec 30, 2024 | Buy | +10,000 | $1.20 | $12.00K | 137,553 |
| Andrew Combs Chief Chemistry Officer | Dec 23, 2024 | Buy | +60,000 | $1.37 | $82.20K | 377,623 |
| Andrew Combs Chief Chemistry Officer | Dec 20, 2024 | Buy | +3,075 | $1.15 | $3.54K | 317,623 |
| Krishna Vaddi CEO, Director | Dec 19, 2024 | Buy | +6,888 | $0.89 | $6.13K | 127,553 |
| Bryant David Lim CLO, Interim CFO, Corp Sec. | Dec 19, 2024 | Buy | +25,000 | $0.91 | $22.75K | 27,400 |
| Krishna Vaddi CEO, Director | Dec 18, 2024 | Buy | +100,000 | $0.93 | $93.00K | 1,167,275 |
| Jane Huang President, CMO | Oct 4, 2024 | Option exercise | +9,375 | – | – | 66,690 |
| Jane Huang President, CMO | Oct 4, 2024 | Tax withholding | −3,349 | $2.00 | $6.70K | 63,341 |
| Jane Huang President, CMO | Jul 4, 2024 | Tax withholding | −3,347 | $3.60 | $12.05K | 57,315 |
| Jane Huang President, CMO | Jul 4, 2024 | Option exercise | +9,375 | – | – | 60,662 |
| Jane Huang President, CMO | Apr 4, 2024 | Tax withholding | −3,347 | $4.74 | $15.86K | 51,287 |
| Jane Huang President, CMO | Apr 4, 2024 | Option exercise | +9,375 | – | – | 54,634 |
| Jane Huang President, CMO | Jan 4, 2024 | Tax withholding | −3,844 | $3.77 | $14.49K | 45,259 |
| Jane Huang President, CMO | Jan 4, 2024 | Option exercise | +9,375 | – | – | 49,103 |
| Jane Huang President, CMO | Oct 4, 2023 | Option exercise | +9,375 | – | – | 39,728 |
| Jane Huang President, CMO | Jul 4, 2023 | Tax withholding | −3,242 | $4.65 | $15.08K | 30,353 |
| Jane Huang President, CMO | Jul 4, 2023 | Option exercise | +9,375 | – | – | 33,595 |
| Krishna Vaddi CEO, Director | May 25, 2023 | Buy | +900 | $5.31 | $4.78K | 1,067,275 |
| Krishna Vaddi CEO, Director | May 24, 2023 | Buy | +1,000 | $5.01 | $5.01K | 1,066,375 |
| Bryant David Lim Chief Legal Officer, Corp Sec. | May 24, 2023 | Buy | +2,400 | $5.39 | $12.94K | 2,400 |
| Laurent Chardonnet Chief Financial Officer | May 23, 2023 | Buy | +5,000 | $5.50 | $27.50K | 42,165 |
| Krishna Vaddi CEO, Director | May 23, 2023 | Buy | +11,856 | $5.63 | $66.75K | 1,065,375 |
| Capital Llc Orbimed Director, 10% owner | May 22, 2023 | Buy | +869,565 | $5.75 | $5.00M | 10,119,756 |
| David P. Bonita Director, 10% owner | May 22, 2023 | Buy | +869,565 | $5.75 | $5.00M | 10,119,756 |
| Jane Huang President, CMO | Apr 6, 2023 | Sale | −13,280 | $6.12 | $81.27K | 24,220 |
| Jane Huang President, CMO | Apr 4, 2023 | Option exercise | +37,500 | – | – | 37,500 |
| Krishna Vaddi CEO, Director | Dec 20, 2022 | Buy | +19,188 | $5.13 | $98.43K | 120,665 |
| Laurent Chardonnet Chief Financial Officer | Dec 8, 2022 | Buy | +10,000 | $4.76 | $47.60K | 35,873 |
| Laurent Chardonnet Chief Financial Officer | Jun 1, 2022 | Buy | +10,000 | $4.23 | $42.30K | 24,500 |
| Andrew Combs EVP, Head of Chemistry | Mar 31, 2022 | Option exercise | +36,062 | $1.89 | $68.16K | 304,442 |
| Laurent Chardonnet Chief Financial Officer | Mar 21, 2022 | Award | +6,500 | $7.51 | $48.82K | 14,500 |
| Deborah Morosini EVP, Chief of Clinical Affairs | Dec 15, 2021 | Option exercise | +3,016 | $1.89 | $5.70K | 3,460 |
| Deborah Morosini EVP, Chief of Clinical Affairs | Dec 15, 2021 | Sale(10b5-1 plan) | −28,751 | $13.00 | $373.76K | 444 |
| Deborah Morosini EVP, Chief of Clinical Affairs | Dec 15, 2021 | Option exercise | +25,735 | $12.85 | $330.69K | 29,195 |
| Andrew Combs EVP, Head of Chemistry | Dec 14, 2021 | Buy | +4,000 | $11.60 | $46.40K | 268,380 |
| Andrew Combs EVP, Head of Chemistry | Dec 13, 2021 | Buy | +4,000 | $12.12 | $48.48K | 264,380 |
| Krishna Vaddi President, CEO, Director | Dec 13, 2021 | Award | +8,000 | $12.13 | $97.04K | 1,053,519 |
| Laurent Chardonnet Chief Financial Officer | Dec 13, 2021 | Award | +5,000 | $12.28 | $61.40K | 8,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Prelude Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,479 shares on Aug 21, 2026 over the last 90 days.
See a number that looks wrong?